Akasofu M, Kawahara E, Kurumaya H, Nakanishi I
Department of Pathology, School of Medicine, Kanazawa University, Japan.
Acta Pathol Jpn. 1993 Dec;43(12):736-44. doi: 10.1111/j.1440-1827.1993.tb02560.x.
The present study was performed to evaluate the diagnostic reliability of antibodies to breast carcinoma-specific antigen and antibodies to cytokeratin catalogue in a metastatic hepatic lesion. Immunohistochemical examinations using antibodies to gross cystic disease fluid protein-15 (GCDFP-15), BCA-225 (a glycoprotein secreted by T47D breast carcinoma cell line) and BRST-5 (a glycoprotein identified in SK-BR-7 breast carcinoma cell line), anti-cytokeratin monoclonal antibodies of MA904, AE3, CAM5.2, PKK1 and cytokeratin 19, and polyclonal anti-keratin antibodies were done. These were on 15 cases of primary breast carcinoma, eight cases of metastatic breast carcinoma in the liver, five cases of cholangiocarcinoma, eight cases of hepatocellular carcinoma and 11 cases of metastatic adenocarcinoma of another primary tumor in the liver. Results showed that GCDFP-15 antigen was most reliable: it was 100% positive in both primary and metastatic breast carcinomas unrelated to histological subtypes, and 100% negative in primary or other metastatic carcinomas in the liver. BCA-225 antigen was detected in high amounts in breast carcinomas (100%, 23/23), but it was positive in cholangiocarcinomas (80%, 4/5) and another metastatic carcinoma in the liver (64%, 7/11). BRST-5 was specifically positive in breast carcinomas but the positivity was low (13%, 3/23). Cytokeratin 19 and keratin were useful to discriminate hepatocellular carcinomas (0%, 0/8) from breast carcinomas (87%, 20/23; 96%, 22/23), but they were also positive in cholangiocarcinomas (100%, 5/5) and other metastatic carcinomas in the liver (91%, 10/11).(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在评估乳腺癌特异性抗原抗体和细胞角蛋白分类抗体在肝转移瘤中的诊断可靠性。使用抗大体囊肿病液体蛋白-15（GCDFP-15）、BCA-225（一种由T47D乳腺癌细胞系分泌的糖蛋白）和BRST-5（一种在SK-BR-7乳腺癌细胞系中鉴定出的糖蛋白）抗体、MA904、AE3、CAM5.2、PKK1抗细胞角蛋白单克隆抗体以及细胞角蛋白19和多克隆抗角蛋白抗体进行免疫组化检查。这些检查应用于15例原发性乳腺癌、8例肝转移性乳腺癌、5例胆管癌、8例肝细胞癌以及11例肝脏中其他原发性肿瘤的转移性腺癌。结果显示，GCDFP-15抗原最为可靠：在与组织学亚型无关的原发性和转移性乳腺癌中均为100%阳性，而在肝脏原发性或其他转移性癌中均为100%阴性。BCA-225抗原在乳腺癌中大量检出（100%，23/23），但在胆管癌中呈阳性（80%，4/5）以及在肝脏中另一种转移性癌中呈阳性（64%，7/11）。BRST-5在乳腺癌中呈特异性阳性，但阳性率较低（13%，3/23）。细胞角蛋白19和角蛋白有助于鉴别肝细胞癌（0%，0/8）与乳腺癌（87%，20/23；96%，22/23），但它们在胆管癌（100%，5/5）和肝脏中其他转移性癌中也呈阳性（91%，10/11）。（摘要截断于250字）
